Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.

Gianos E, Schoenthaler A, Guo Y, Zhong J, Weintraub H, Schwartzbard A, Underberg J, Schloss M, Newman JD, Heffron S, Fisher EA, Berger JS.

Am Heart J. 2018 May;199:37-43. doi: 10.1016/j.ahj.2017.12.019. Epub 2018 Jan 9.

PMID:
29754664
2.

The 2017 high blood pressure clinical practice guideline: The old and the new.

Schwartzbard AZ, Newman JD, Weintraub HS, Baum SJ.

Clin Cardiol. 2018 Mar;41(3):279-281. doi: 10.1002/clc.22905. Epub 2018 Mar 25. No abstract available.

3.

Cardiovascular disease leads to a new algorithm for diabetes treatment.

Rodriguez V, Weiss MC, Weintraub H, Goldberg IJ, Schwartzbard A.

J Clin Lipidol. 2017 Sep - Oct;11(5):1126-1133. doi: 10.1016/j.jacl.2017.07.004. Epub 2017 Jul 22. Review.

PMID:
28822714
4.

Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention.

Weiss MC, Berger JS, Gianos E, Fisher E, Schwartzbard A, Underberg J, Weintraub H.

J Clin Lipidol. 2017 Sep - Oct;11(5):1177-1180. doi: 10.1016/j.jacl.2017.07.005. Epub 2017 Jul 22.

PMID:
28801030
5.

Primary Prevention of Cardiovascular Disease in Diabetes Mellitus.

Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS.

J Am Coll Cardiol. 2017 Aug 15;70(7):883-893. doi: 10.1016/j.jacc.2017.07.001. Review.

PMID:
28797359
6.

Diabetes mellitus is a coronary heart disease risk equivalent for peripheral vascular disease.

Newman JD, Rockman CB, Kosiborod M, Guo Y, Zhong H, Weintraub HS, Schwartzbard AZ, Adelman MA, Berger JS.

Am Heart J. 2017 Feb;184:114-120. doi: 10.1016/j.ahj.2016.09.002. Epub 2016 Sep 18.

7.

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials.

Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, Messerli FH.

Am J Med. 2017 Jun;130(6):707-719.e8. doi: 10.1016/j.amjmed.2017.01.004. Epub 2017 Jan 19.

PMID:
28109971
8.

Cardiovascular Effects of the New Weight Loss Agents.

Vorsanger MH, Subramanyam P, Weintraub HS, Lamm SH, Underberg JA, Gianos E, Goldberg IJ, Schwartzbard AZ.

J Am Coll Cardiol. 2016 Aug 23;68(8):849-59. doi: 10.1016/j.jacc.2016.06.007. Review.

9.

The Editor's Round Table: Current Perspectives on Triglycerides and Atherosclerosis.

Friedewald VE, Jones PH, Mason P, Roberts R, Weintraub H.

Am J Cardiol. 2016 May 15;117(10):1697-1702. doi: 10.1016/j.amjcard.2016.02.025. Epub 2016 Mar 2. No abstract available.

PMID:
27142496
10.

Management of Hypogonadism in Cardiovascular Patients: What Are the Implications of Testosterone Therapy on Cardiovascular Morbidity?

Tanna MS, Schwartzbard A, Berger JS, Underberg J, Gianos E, Weintraub HS.

Urol Clin North Am. 2016 May;43(2):247-60. doi: 10.1016/j.ucl.2016.01.011. Epub 2016 Mar 10. Review.

PMID:
27132583
11.

Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.

Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH.

Mayo Clin Proc. 2016 Jan;91(1):51-60. doi: 10.1016/j.mayocp.2015.10.019.

PMID:
26763511
12.

Reply to Letters Regarding Article, "Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)".

Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ, Bangalore S.

Circulation. 2015 May 12;131(19):e473. doi: 10.1161/CIRCULATIONAHA.114.014177. No abstract available.

13.

Prevalence of unrecognized diabetes, prediabetes and metabolic syndrome in patients undergoing elective percutaneous coronary intervention.

Balakrishnan R, Berger JS, Tully L, Vani A, Shah B, Burdowski J, Fisher E, Schwartzbard A, Sedlis S, Weintraub H, Underberg JA, Danoff A, Slater JA, Gianos E.

Diabetes Metab Res Rev. 2015 Sep;31(6):603-9. doi: 10.1002/dmrr.2646. Epub 2015 May 12.

14.

The role of testosterone therapy in cardiovascular mortality: culprit or innocent bystander?

Tanna MS, Schwartzbard A, Berger JS, Alukal J, Weintraub H.

Curr Atheroscler Rep. 2015 Mar;17(3):490. doi: 10.1007/s11883-015-0490-0. Review.

PMID:
25687258
15.

Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.

Weintraub HS.

Postgrad Med. 2014 Nov;126(7):7-18. doi: 10.3810/pgm.2014.11.2828. Review.

PMID:
25387209
16.

Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention.

Tully L, Gianos E, Vani A, Guo Y, Balakrishnan R, Schwartzbard A, Slater J, Stein R, Underberg J, Weintraub H, Fisher E, Berger JS.

Am Heart J. 2014 Sep;168(3):310-316.e3. doi: 10.1016/j.ahj.2014.05.011. Epub 2014 Jun 2.

PMID:
25173542
17.

Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III).

Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ, Bangalore S.

Circulation. 2014 Aug 12;130(7):546-53. doi: 10.1161/CIRCULATIONAHA.114.010001. Epub 2014 Jul 11.

18.

A current approach to statin intolerance.

Tompkins R, Schwartzbard A, Gianos E, Fisher E, Weintraub H.

Clin Pharmacol Ther. 2014 Jul;96(1):74-80. doi: 10.1038/clpt.2014.84. Epub 2014 Apr 11. Review.

PMID:
24727470
19.

Diabetes and vascular disease in different arterial territories.

Shah B, Rockman CB, Guo Y, Chesner J, Schwartzbard AZ, Weintraub HS, Adelman MA, Riles TS, Berger JS.

Diabetes Care. 2014 Jun;37(6):1636-42. doi: 10.2337/dc13-2432. Epub 2014 Apr 4.

20.

Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.

Weintraub H.

Atherosclerosis. 2013 Oct;230(2):381-9. doi: 10.1016/j.atherosclerosis.2013.07.041. Epub 2013 Jul 31. Review.

21.

Use of ambulatory blood pressure monitoring to guide hypertensive therapy.

Singh A, Gianos E, Schwartzbard A, Black H, Weintraub H.

Curr Treat Options Cardiovasc Med. 2013 Dec;15(6):746-60. doi: 10.1007/s11936-013-0255-4.

PMID:
23839274
22.

Effect of strict glycemic control in patients with diabetes mellitus on frequency of macrovascular events.

Singh A, Donnino R, Weintraub H, Schwartzbard A.

Am J Cardiol. 2013 Oct 1;112(7):1033-8. doi: 10.1016/j.amjcard.2013.05.044. Epub 2013 Jun 14. Review.

PMID:
23768455
23.

What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?

Singh A, Schwartzbard A, Gianos E, Berger JS, Weintraub H.

Curr Treat Options Cardiovasc Med. 2013 Feb;15(1):104-17. doi: 10.1007/s11936-012-0220-7.

PMID:
23109123
24.

Home and clinic blood pressure responses in elderly individuals with systolic hypertension.

Cushman WC, Duprez DA, Weintraub HS, Purkayastha D, Zappe D, Samuel R, Izzo JL Jr.

J Am Soc Hypertens. 2012 May-Jun;6(3):210-8. doi: 10.1016/j.jash.2012.03.001.

PMID:
22520932
25.

Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity.

Weintraub HS, Duprez DA, Cushman WC, Zappe DH, Purkayastha D, Samuel R, Izzo JL Jr.

Cardiovasc Drugs Ther. 2012 Apr;26(2):145-55. doi: 10.1007/s10557-011-6365-x.

PMID:
22311004
26.

The Role of Statin Therapy for Primary Prevention: What is the Evidence?

Ascunce RR, Berger JS, Weintraub HS, Schwartzbard A.

Curr Atheroscler Rep. 2012 Jan 29. [Epub ahead of print]

PMID:
22286194
27.

Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results.

Izzo JL Jr, Weintraub HS, Duprez DA, Purkayastha D, Zappe D, Samuel R, Cushman WC.

J Clin Hypertens (Greenwich). 2011 Oct;13(10):722-30. doi: 10.1111/j.1751-7176.2011.00498.x. Epub 2011 Jul 14.

28.

Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy.

Duprez DA, Weintraub HS, Cushman WC, Purkayastha D, Zappe D, Samuel R, Izzo JL Jr.

Blood Press Monit. 2011 Aug;16(4):186-96. doi: 10.1097/MBP.0b013e32834944e9.

PMID:
21747241
29.

Role of RAAS Inhibition in the Prevention of Cardiovascular Disease.

Tran HA, Schwartzbard A, Weintraub HS.

Curr Treat Options Cardiovasc Med. 2011 Aug;13(4):279-88. doi: 10.1007/s11936-011-0126-9.

PMID:
21494840
30.

Potential benefits of aliskiren beyond blood pressure reduction.

Weintraub HS, Tran H, Schwartzbard A.

Cardiol Rev. 2011 Mar-Apr;19(2):90-4. doi: 10.1097/CRD.0b013e318204d9ae. Review.

PMID:
21285669
31.

Ranolazine: a new approach to treating an old problem.

Reddy BM, Weintraub HS, Schwartzbard AZ.

Tex Heart Inst J. 2010;37(6):641-7. Review.

32.

Fish oil for the treatment of cardiovascular disease.

Weitz D, Weintraub H, Fisher E, Schwartzbard AZ.

Cardiol Rev. 2010 Sep-Oct;18(5):258-63. doi: 10.1097/CRD.0b013e3181ea0de0. Review.

33.

Combination therapy for managing difficult-to-treat patients with stage 2 hypertension: focus on valsartan-based combinations.

Weintraub HS, Rudolph A.

Am J Ther. 2011 Nov;18(6):e227-43. doi: 10.1097/MJT.0b013e3181da0437. Review.

PMID:
20535014
34.

Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.

Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Lerman A, McConnell JP, Weintraub HS.

Am J Cardiol. 2008 Jun 16;101(12A):51F-57F. doi: 10.1016/j.amjcard.2008.04.019. Review.

PMID:
18549872
35.

Identifying the vulnerable patient with rupture-prone plaque.

Weintraub HS.

Am J Cardiol. 2008 Jun 16;101(12A):3F-10F. doi: 10.1016/j.amjcard.2008.04.013.

PMID:
18549869
36.

The pleiotropic effects of antihypertensive agents: do they account for additional cardiovascular benefit beyond BP reduction?

Weintraub HS, Basile J.

South Med J. 2008 Aug;101(8):818-23. doi: 10.1097/SMJ.0b013e31817b6622.

PMID:
18622353
37.

Fibrate therapy: an update.

Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A.

Cardiol Rev. 2008 May-Jun;16(3):129-41. doi: 10.1097/CRD.0b013e31816b43d3. Review.

PMID:
18414184
38.

Treatment of multiple-risk patients: using combination therapy to treat beyond LDL lowering.

Weintraub HS.

Curr Hypertens Rep. 2005 Aug;7(4):265-70. Review.

PMID:
16061044
39.

DNA dendrimers localize MyoD mRNA in presomitic tissues of the chick embryo.

Gerhart J, Baytion M, DeLuca S, Getts R, Lopez C, Niewenhuis R, Nilsen T, Olex S, Weintraub H, George-Weinstein M.

J Cell Biol. 2000 May 15;149(4):825-34.

40.

Designing, constructing and utilizing of new learning spaces: space as a place to think with.

Weintraub H.

Turk J Pediatr. 1999;41 Suppl:119-25. No abstract available.

PMID:
10770083
41.
42.

Intramolecular regulation of MyoD activation domain conformation and function.

Huang J, Weintraub H, Kedes L.

Mol Cell Biol. 1998 Sep;18(9):5478-84.

43.

I-mf, a novel myogenic repressor, interacts with members of the MyoD family.

Chen CM, Kraut N, Groudine M, Weintraub H.

Cell. 1996 Sep 6;86(5):731-41.

44.

Gene trapping in differentiating cell lines: regulation of the lysosomal protease cathepsin B in skeletal myoblast growth and fusion.

Gogos JA, Thompson R, Lowry W, Sloane BF, Weintraub H, Horwitz M.

J Cell Biol. 1996 Aug;134(4):837-47.

45.
46.
47.

Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain.

Kopan R, Schroeter EH, Weintraub H, Nye JS.

Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1683-8.

48.

Skeletal myogenesis: the preferred pathway of chick embryo epiblast cells in vitro.

George-Weinstein M, Gerhart J, Reed R, Flynn J, Callihan B, Mattiacci M, Miehle C, Foti G, Lash JW, Weintraub H.

Dev Biol. 1996 Jan 10;173(1):279-91.

49.

MyoD forms micelles which can dissociate to form heterodimers with E47: implications of micellization on function.

Laue TM, Starovasnik MA, Weintraub H, Sun XH, Snider L, Klevit RE.

Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11824-8.

Supplemental Content

Loading ...
Support Center